Covidien's Optistar Elite contrast delivery system injects contrast media-related drugs into a patient’s vascular system to aid in obtaining diagnostic images when used with magnetic resonance (MR) imaging equipment.

The Optistar Elite aims to provide improved performance and ease of use, compared with the previous Optistar LE model. Among the features on the Optistar Elite injector is patency check, which aids in preventing extravasation, assists in reducing the potential of certain medical errors and helps enhance clinical and work flow efficiency.


Additional Content

News | Contrast Media

Oct. 27, 2026 – Bracco has announced plans to invest $230 million to establish its first U.S. manufacturing facility for ...

Time October 28, 2026
arrow
News | Cardiac Imaging

Aug. 11, 2026 — Bracco Imaging recently announced that VueJect, its dedicated ultrasound contrast delivery system ...

Time August 12, 2026
arrow
News | Contrast Agents

June 15, 2026 – Bayer has announced that the U.S. Food and Drug Administration (FDA) approved Ambelvist (gadoquatrane) ...

Time June 16, 2026
arrow
News | FDA

May 18, 2026 — ACIST Medical Systems, a Bracco company, has received U.S. Food and Drug Administration (FDA) clearance ...

Time May 18, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 4, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Bayer for the expanded ...

Time March 04, 2026
arrow
Subscribe Now